Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865328 | 1.00 | MAPT (0.47) | MAPTMEN1KMT2ATDP1HCAR3 | |
| SCHEMBL864751 | 0.87 | MAPT (0.57) | MAPTHCAR3LMNAKDM4EGAA | |
| SCHEMBL864589 | 0.86 | MAPT (0.54) | MAPTMEN1KMT2ATDP1HCAR3 | |
| SCHEMBL864175 | 0.86 | MAPT (0.43) | MAPTHCAR3LMNAKDM4EPRSS1 | |
| SCHEMBL1838155 | 0.81 | MAPT (0.50) | MAPTMEN1KMT2ATDP1HCAR3 | |
| SCHEMBL864917 | 0.81 | KDM4E (0.40) | MAPTKMT2ALMNAKDM4EPRSS1 | |
| SCHEMBL1838157 | 0.81 | MAPT (0.50) | MAPTMEN1KMT2ATDP1HCAR3 | |
| SCHEMBL2553696 | 0.80 | MAPT (0.49) | MAPTMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL3380574 | 0.79 | MAPT (0.47) | MAPTMEN1KMT2ATDP1HCAR3 | |
| SCHEMBL3380564 | 0.79 | MAPT (0.47) | MAPTMEN1KMT2ATDP1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | MAPT 4674/4885MEN1 4416/4885KMT2A 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.